24.00
price up icon0.88%   0.21
 
loading
Biodesix Inc stock is traded at $24.00, with a volume of 72,415. It is up +0.88% in the last 24 hours and up +13.58% over the past month. Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$23.79
Open:
$23.88
24h Volume:
72,415
Relative Volume:
1.00
Market Cap:
$253.23M
Revenue:
$96.10M
Net Income/Loss:
$-31.96M
P/E Ratio:
-5.9602
EPS:
-4.0267
Net Cash Flow:
$-25.27M
1W Performance:
+2.13%
1M Performance:
+13.58%
6M Performance:
+109.61%
1Y Performance:
+202.27%
1-Day Range:
Value
$23.59
$24.43
1-Week Range:
Value
$23.32
$25.52
52-Week Range:
Value
$5.26
$25.52

Biodesix Inc Stock (BDSX) Company Profile

Name
Name
Biodesix Inc
Name
Phone
303-417-0500
Name
Address
919 WEST DILLON ROAD, LOUISVILLE
Name
Employee
334
Name
Twitter
Name
Next Earnings Date
2026-08-05
Name
Latest SEC Filings
Name
BDSX's Discussions on Twitter

Compare BDSX vs TMO, DHR, NTRA, IDXX, A

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BDSX icon
BDSX
Biodesix Inc
24.00 255.55M 96.10M -31.96M -25.27M -4.0267
TMO icon
TMO
Thermo Fisher Scientific Inc
588.29 222.96B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
202.45 144.67B 24.78B 3.68B 5.29B 5.1743
NTRA icon
NTRA
Natera Inc
309.93 45.54B 2.50B -226.32M 71.51M -1.6412
IDXX icon
IDXX
Idexx Laboratories Inc
550.96 44.95B 4.45B 1.10B 1.06B 13.59
A icon
A
Agilent Technologies Inc
148.53 41.87B 7.23B 1.41B 1.09B 4.979

Biodesix Inc Stock (BDSX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-27-26 Upgrade William Blair Mkt Perform → Outperform
May-14-25 Downgrade William Blair Outperform → Mkt Perform
Sep-16-24 Initiated Scotiabank Sector Outperform
Jul-26-24 Initiated Craig Hallum Buy
May-13-24 Initiated TD Cowen Buy
May-03-24 Initiated Lake Street Buy
Nov-17-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-23-20 Initiated BTIG Research Buy
Nov-23-20 Initiated Canaccord Genuity Buy
Nov-23-20 Initiated Morgan Stanley Overweight
Nov-23-20 Initiated William Blair Outperform
View All

Biodesix Inc Stock (BDSX) Latest News

pulisher
Aug 13, 2026

Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan

Aug 13, 2026
pulisher
Aug 13, 2026

Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026
pulisher
Aug 12, 2026

Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com

Aug 12, 2026
pulisher
Aug 12, 2026

Biodesix at Canaccord Genuity conference: growth, margins in focus By Investing.com - Investing.com Nigeria

Aug 12, 2026
pulisher
Aug 12, 2026

Biodesix (BDSX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 12, 2026
pulisher
Aug 12, 2026

Biodesix (BDSX) major holder Jack W. Schuler adds shares via trusts - Stock Titan

Aug 12, 2026
pulisher
Aug 12, 2026

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference - TradingView

Aug 12, 2026
pulisher
Aug 11, 2026

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance

Aug 11, 2026
pulisher
Aug 11, 2026

Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 11, 2026
pulisher
Aug 10, 2026

Canaccord raises Biodesix stock price target on strong test volume By Investing.com - Investing.com India

Aug 10, 2026
pulisher
Aug 10, 2026

Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet - Yahoo Finance

Aug 10, 2026
pulisher
Aug 10, 2026

BDSX Maintained by Canaccord Genuity -- Price Target Raised to $35 - GuruFocus

Aug 10, 2026
pulisher
Aug 10, 2026

Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat

Aug 10, 2026
pulisher
Aug 10, 2026

Canaccord raises Biodesix stock price target on strong test volume - Investing.com India

Aug 10, 2026
pulisher
Aug 10, 2026

HC Wainwright Forecasts Biodesix's Q3 Earnings (NASDAQ:BDSX) - MarketBeat

Aug 10, 2026
pulisher
Aug 08, 2026

Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67 - simplywall.st

Aug 08, 2026
pulisher
Aug 08, 2026

H.C. Wainwright Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $27 - Moomoo

Aug 08, 2026
pulisher
Aug 07, 2026

Biodesix Inc (BDSX) Stock News Today - TradingKey

Aug 07, 2026
pulisher
Aug 07, 2026

Biodesix boosts sales, trims loss as diagnostics firm pushes toward profitability - BizWest

Aug 07, 2026
pulisher
Aug 07, 2026

A Quick Look at Today's Ratings for Biodesix(BDSX.US), With a Forecast Between $27 to $40 - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

Biodesix (BDSX) Stock Pullback Puts Focus On Losses Despite Stronger Margins - Sahm

Aug 07, 2026
pulisher
Aug 06, 2026

BDSX Maintains Buy Rating -- Price Target Raised to $27.00 by HC Wainwright - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Biodesix, Inc. Stock 12‑Month Price Target Raised to $32.67, Implies 43% Upside - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Biodesix, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

William Blair Initiates Biodesix(BDSX.US) With Buy Rating - Moomoo

Aug 06, 2026
pulisher
Aug 06, 2026

Biodesix earnings beat by $0.19, revenue topped estimates - Investing.com South Africa

Aug 06, 2026
pulisher
Aug 06, 2026

Earnings call transcript: Biodesix tops revenue forecast in Q2 2026, shares fall after hours - Investing.com Nigeria

Aug 06, 2026
pulisher
Aug 06, 2026

Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic Testing Growth - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic ... - Yahoo Finance

Aug 06, 2026
pulisher
Aug 05, 2026

Is Biodesix Inc (BDSX) Overvalued After Q2 2026 Earnings Beat? G - GuruFocus

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix Q2 Earnings Call Highlights - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix (NASDAQ:BDSX) Announces Earnings Results - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix Q2 2026 earnings: Diagnostic testing growth narrows losses - TradingKey

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix (NASDAQ:BDSX) Q2 EPS Beats, Revenue In Line, Shares Slip - ChartMill

Aug 05, 2026
pulisher
Aug 05, 2026

BIODESIX ($BDSX) Releases Q2 2026 Earnings - Moomoo

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix Q2 revenue rises 34%, beats analyst estimates - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix Posts Q2 2026 Revenue $26.9M; Gross Margin 82%, Adjusted EBITDA Loss Narrows - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

BIODESIX Inc Q2 2026: Revenue $26.86M, EPS $(0.71) — 10-Q Summary - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix Announces Second Quarter 2026 Results and Highlights - The Manila Times

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix (NASDAQ: BDSX) lifts lung test revenue and raises $23.9M equity - Stock Titan

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 05, 2026
pulisher
Aug 05, 2026

Biodesix (Nasdaq: BDSX) grows Q2 2026 revenue 34% to $26.9M - Stock Titan

Aug 05, 2026
pulisher
Aug 05, 2026

BRIEF-Biodesix Q2 Net Income USD -7.273 Million - TradingView

Aug 05, 2026

Biodesix Inc Stock (BDSX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
DGX DGX
$234.40
price down icon 0.69%
MTD MTD
$1,419.02
price down icon 0.82%
$190.89
price down icon 0.91%
IQV IQV
$236.66
price down icon 2.01%
WAT WAT
$412.17
price down icon 0.32%
A A
$148.53
price down icon 0.51%
Cap:     |  Volume (24h):